Bolt Biotherapeutics (NASDAQ:BOLT) Coverage Initiated at Jonestrading

Analysts at Jonestrading started coverage on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a note issued to investors on Friday, Analyst Ratings Network reports. The firm set a “buy” rating and a $45.00 price target on the stock. Jonestrading’s price objective points to a potential upside of 249.38% from the stock’s previous close.

A number of other analysts have also weighed in on BOLT. SVB Leerink upped their target price on shares of Bolt Biotherapeutics from $34.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, August 16th. Zacks Investment Research lowered shares of Bolt Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 17th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Bolt Biotherapeutics has an average rating of “Buy” and an average target price of $41.40.

NASDAQ:BOLT opened at $12.88 on Friday. The company has a market cap of $479.15 million and a price-to-earnings ratio of -0.58. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.89 and a current ratio of 12.89. The stock’s fifty day moving average price is $14.30 and its two-hundred day moving average price is $19.29. Bolt Biotherapeutics has a 52-week low of $10.75 and a 52-week high of $43.07.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Wednesday, August 11th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.21). On average, equities analysts predict that Bolt Biotherapeutics will post -2.61 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at $28,000. Royal Bank of Canada bought a new position in shares of Bolt Biotherapeutics during the 1st quarter valued at $39,000. Rokos Capital Management LLP purchased a new stake in Bolt Biotherapeutics during the 1st quarter valued at $149,000. Morgan Stanley purchased a new stake in Bolt Biotherapeutics during the 1st quarter valued at $156,000. Finally, New York State Common Retirement Fund boosted its position in Bolt Biotherapeutics by 40.3% during the 2nd quarter. New York State Common Retirement Fund now owns 11,508 shares of the company’s stock valued at $178,000 after buying an additional 3,308 shares during the period. 86.36% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.

Recommended Story: Trade War

Analyst Recommendations for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.